Top stations Podcasts Live sports Near you Genres Topics

Podcasts Health & WellnessCME in Minutes: Education in Dermatology

Listen to this podcast for free in the app:

radio.net

Sleep timer

Save favourites

Download for free in the App Store

CME in Minutes: Education in Dermatology

Answers in CME

Health & Wellness Science

CME in Minutes: Education in Dermatology

Latest episode

50 episodes

Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care
2025/12/17 | 19 mins.
Please visit answersincme.com/NHE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care
2025/12/17 | 19 mins.
Please visit answersincme.com/NEH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
Sheilagh M. Maguiness, MD, FAAP / Elizabeth Vainder, MD, FAAP - Escalating Atopic Dermatitis Treatment in Pediatric Patients With Confidence: What Do the Guidelines Tell Us?
2025/12/10 | 18 mins.
Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.
Tina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape
2025/12/09 | 1h 1 mins.
Please visit answersincme.com/860/99534447-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.
April W. Armstrong, MD, MPH / Linda Stein Gold, MD / Clive M. Liu, MD - Personalizing Psoriasis Care Across the Map: Navigating Regional Barriers to Integrating Oral Small Molecule Treatment for Moderate to Severe Disease
2025/12/03 | 1h 4 mins.
Please visit answersincme.com/860/99505211-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in psoriasis discuss real‑world strategies for using oral small molecules in moderate to severe disease. Upon completion of this activity, participants should be better able to: Identify patients with moderate to severe plaque psoriasis who would benefit from oral small molecule therapy; Differentiate the targets/mechanisms of action of available oral small molecule therapy for moderate to severe plaque psoriasis; and Integrate strategies to individualize oral small molecule therapy for moderate to severe plaque psoriasis, while balancing safety, considering regional barriers.

More Health & Wellness podcasts

Trending Health & Wellness podcasts

About CME in Minutes: Education in Dermatology

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Dermatology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for dermatologists to cover the diagnosis, treatment, follow-up, and clinical management of various skin conditions. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

Podcast website

Health & Wellness Science Life Sciences Medicine